Spravato (Esketamine) for Treatment-Resistant Depression: What Miami Patients Need to Know

For millions of Americans, standard antidepressants simply don't work. If you've tried two or more antidepressants without meaningful relief, you may have treatment-resistant depression (TRD) — and Spravato (esketamine) may be the breakthrough you've been waiting for.

Para millones de estadounidenses, los antidepresivos estándar simplemente no funcionan. Si ha probado dos o más antidepresivos sin alivio significativo, puede tener depresión resistente al tratamiento (TRD) — y Spravato (esketamina) puede ser el avance que ha estado esperando.

Spravato is the brand name for esketamine, an FDA-approved nasal spray derived from ketamine. Unlike traditional antidepressants that target serotonin or norepinephrine, Spravato works on the NMDA glutamate receptor — a completely different pathway in the brain.

This means it can work within hours to days, not the 4–8 weeks typical antidepressants require.

FDA Approvals:

• 2019: Treatment-resistant depression (TRD) in adults
• 2020: Major depressive disorder with acute suicidal ideation or behavior (MDSI)

Spravato es el nombre comercial de la esketamina, un aerosol nasal aprobado por la FDA derivado de la ketamina. A diferencia de los antidepresivos tradicionales, Spravato actúa sobre el receptor NMDA de glutamato, lo que significa que puede funcionar en horas o días, no en las 4–8 semanas que requieren los antidepresivos típicos.

Spravato promotes neuroplasticity — the brain's ability to form new neural connections. In people with depression, certain brain circuits become rigid and dysfunctional. Esketamine rapidly restores synaptic connections in the prefrontal cortex, the region responsible for mood regulation, decision-making, and emotional processing.

Think of it as a "reset" for the brain's communication network.

Spravato promueve la neuroplasticidad — la capacidad del cerebro para formar nuevas conexiones neuronales. En personas con depresión, ciertos circuitos cerebrales se vuelven rígidos y disfuncionales. La esketamina restaura rápidamente las conexiones sinápticas en la corteza prefrontal.

You may be a candidate if you:

• Have been diagnosed with Major Depressive Disorder (MDD)
• Have tried at least two different antidepressants at adequate doses without sufficient improvement
• Are currently taking an oral antidepressant (Spravato is used alongside, not instead of, oral medication)
• Are 18 years of age or older

Also approved for:

• Adults with MDD experiencing active suicidal thoughts or behaviors (used in a monitored clinical setting)

Puede ser candidato si tiene diagnóstico de Trastorno Depresivo Mayor, ha probado al menos dos antidepresivos diferentes sin mejoría suficiente, y actualmente toma un antidepresivo oral. También está aprobado para adultos con MDD que experimentan pensamientos suicidas activos.

Spravato is administered in a certified healthcare setting — you cannot take it home. Here's the typical protocol:

Induction Phase (Weeks 1–4):

• 2 sessions per week
• Each session: self-administer the nasal spray under supervision
• Monitored for 2 hours post-dose for dissociation, blood pressure changes, or sedation

Maintenance Phase (Weeks 5–8):

• 1 session per week

Ongoing Maintenance:

• 1 session every 1–2 weeks, based on response

Most patients report noticeable improvement within 2–4 sessions. Some feel relief the same day.

Spravato se administra en un entorno de atención médica certificado. La fase de inducción incluye 2 sesiones por semana durante las primeras 4 semanas, seguida de mantenimiento semanal. La mayoría de los pacientes reportan mejoría notable dentro de 2–4 sesiones.

Spravato's FDA approval means it is more likely to be covered by Medicare, Medicaid, and commercial insurance — a significant advantage for patients.

Because Spravato is FDA-approved, it is covered by:

• Medicare (Part B, administered in-office)
• Medicaid (Florida, New York, Texas, Nevada)
• Many commercial insurance plans

Prior authorization is typically required. Our team handles the authorization process for you.

Debido a que Spravato está aprobado por la FDA, está cubierto por Medicare, Medicaid y muchos planes de seguro comercial. Nuestro equipo maneja el proceso de autorización previa por usted.

Common side effects (usually resolve within 2 hours of dosing):

• Dissociation or feeling "detached"
• Dizziness or sedation
• Nausea
• Increased blood pressure (monitored during session)
• Headache

This is why the 2-hour monitoring period is required — and why you cannot drive on the day of treatment.

• Board-certified PMHNPs experienced in treatment-resistant depression
• Bilingual care — evaluations and follow-ups in English and Spanish
• Insurance navigation — we handle prior auth for Medicare, Medicaid, and commercial plans
• Telehealth follow-ups available in FL, NY, TX & NV
• Compassionate, judgment-free care for patients who have struggled for years

Proveedores PMHNP certificados, atención bilingüe, navegación de seguros, seguimiento por telehealth disponible en FL, NY, TX y NV.

If you've been living with depression that hasn't responded to medication, you deserve a new option. Spravato has helped thousands of patients who thought nothing would ever work.

Call 1-866-378-1587 or book online at soluramentalhealth.com to schedule a Spravato evaluation.

Si ha estado viviendo con depresión que no ha respondido a la medicación, merece una nueva opción. Llame al 1-866-378-1587 o reserve en línea para programar una evaluación de Spravato.

This article is for informational purposes only and does not constitute medical advice. Consult a licensed psychiatric provider to determine if Spravato is appropriate for you.